Methyldopa-Induced Autoimmune Antibodies in Pregnant Women—Case Series and Literature Review
- 1Warsaw Institute of Women’s Health, 00-189 Warsaw, Poland
- 2Department of Gynecology, Obstetrics and Gynecological Endocrinology, Center of Postgraduate Medical Education, 01-813 Warsaw, Poland
Abstract
Background: Methyldopa is widely used for the treatment of hypertension during pregnancy because of its established maternal and fetal safety profile. However, it can induce red blood cell autoantibodies, occasionally resulting in autoimmune hemolytic anemia. The aim of this study was to summarize current evidence on methyldopa-associated red blood cell autoantibody formation and autoimmune hemolytic anemia in pregnant women, based on a review of the available literature and observations from our center. Methods: A scoping review was conducted using the PubMed/MEDLINE, Web of Science, and Scopus databases to identify studies addressing autoimmune antibodies or hemolytic anemia associated with methyldopa therapy in pregnancy. Two independent reviewers screened titles and abstracts and assessed full-text articles for eligibility. Disagreements were resolved through discussion with a third reviewer. In addition, citation mapping was performed using the Litmaps tool (Litmaps Ltd.) to expand the set of relevant studies. In addition to the literature findings, two cases from our center, consistent with the scope of this review, were included in the study. Results: Four studies met the inclusion criteria, all of which were case-based. In addition, two cases from our center were included. The available data on six pregnancies suggest that methyldopa may induce the production of autoantibodies with variable clinical expression—most often asymptomatic, although in some cases hemolytic anemia may occur. These autoantibodies can cross the placenta. Neonatal outcomes are likewise heterogeneous, ranging from asymptomatic presentations to hemolysis with associated jaundice. Conclusions: Methyldopa-induced autoantibody formation in pregnancy is often a benign finding; however, it requires careful evaluation to exclude hemolytic anemia. Drug discontinuation appears effective in symptomatic patients, whereas management of asymptomatic cases is not well defined and should be individualized. Further studies are needed to clarify the incidence and guide clinical management.
Related
- Immune Checkpoint Inhibitor Therapy Triggers Autoimmune Cerebellar Ataxia with Anti-P/Q-type VGCC Antibody and Anti-mGluR5 Antibodies: A Case Report
- Efgartigimod-responsive autoimmune peripheral neuropathy with concurrent anti-GM2 IgG and anti-contactin-1 IgG antibodies: a rare case report.
- [Whole blood exchange for a critically ill patient with Hodgkin lymphoma complicated by severe autoimmune hemolytic anemia: a case report and literature review].
- Fondaparinux as an alternative anticoagulant in a pregnant woman with heparin-induced delayed-type hypersensitivity reaction
- Predominance of autoimmune heparin-induced thrombocytopenia in a nephrology department
BibTeX
@article{grycuk2026methyldopainduced,
title = {{Methyldopa-Induced Autoimmune Antibodies in Pregnant Women—Case Series and Literature Review}},
author = {Wiktoria Grycuk and Magdalena Pach and Diana Massalska},
journal = {Journal of Clinical Medicine},
year = {2026},
month = nov,
doi = {10.3390/jcm15218741},
url = {https://www.mdpi.com/2077-0383/15/21/8741},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Methyldopa-Induced Autoimmune Antibodies in Pregnant Women—Case Series and Literature Review
AU - Wiktoria Grycuk
AU - Magdalena Pach
AU - Diana Massalska
PY - 2026
DA - 2026/11/09
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218741
UR - https://www.mdpi.com/2077-0383/15/21/8741
AB - Background: Methyldopa is widely used for the treatment of hypertension during pregnancy because of its established maternal and fetal safety profile. However, it can induce red blood cell autoantibodies, occasionally resulting in autoimmune hemolytic anemia. The aim of this study was to summarize current evidence on methyldopa-associated red blood cell autoantibody formation and autoimmune hemolytic anemia in pregnant women, based on a review of the available literature and observations from our center. Methods: A scoping review was conducted using the PubMed/MEDLINE, Web of Science, and Scopus databases to identify studies addressing autoimmune antibodies or hemolytic anemia associated with methyldopa therapy in pregnancy. Two independent reviewers screened titles and abstracts and assessed full-text articles for eligibility. Disagreements were resolved through discussion with a third reviewer. In addition, citation mapping was performed using the Litmaps tool (Litmaps Ltd.) to expand the set of relevant studies. In addition to the literature findings, two cases from our center, consistent with the scope of this review, were included in the study. Results: Four studies met the inclusion criteria, all of which were case-based. In addition, two cases from our center were included. The available data on six pregnancies suggest that methyldopa may induce the production of autoantibodies with variable clinical expression—most often asymptomatic, although in some cases hemolytic anemia may occur. These autoantibodies can cross the placenta. Neonatal outcomes are likewise heterogeneous, ranging from asymptomatic presentations to hemolysis with associated jaundice. Conclusions: Methyldopa-induced autoantibody formation in pregnancy is often a benign finding; however, it requires careful evaluation to exclude hemolytic anemia. Drug discontinuation appears effective in symptomatic patients, whereas management of asymptomatic cases is not well defined and should be individualized. Further studies are needed to clarify the incidence and guide clinical management.
SN - 2077-0383
ER -